BTN1A1, a member of the butyrophilin group , represents an captivating therapeutic target for various immune disorders. The ICT-01-N297A immunoglobin , specifically designed to recognize BTN1A1, offers a novel https://www.targetmol.com/compound/ict_01_n297a